Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Blood Advances|February 16, 2021
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trialKen Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 4, 2015
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational StudyShigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki, et al.
Internal Medicine (Tokyo, Japan)|February 22, 2021
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study GroupMasahiko Chiwata, Hidehiro Itonaga, Shinya Sato, et al.
Journal of Hepatology|March 21, 2020
Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphomaShigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki, et al.
Internal Medicine (Tokyo, Japan)|July 9, 2025
Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine MonotherapyTakafumi Furumoto, Koji Ando, Eo Toriyama, et al.
Haematologica|October 6, 2022
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
International Journal of Hematology|February 27, 2007
Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, JapanEmi Matsuo, Yasushi Miyazaki, Chizuko Tsutsumi, et al.
Leukemia Research|November 23, 2013
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study GroupHidehiro Itonaga, Hideki Tsushima, Daisuke Imanishi, et al.
International Journal of Hematology|March 7, 2009
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study GroupMari Sakai, Yasushi Miyazaki, Emi Matsuo, et al.
Pageof 15